Opportunities - Transforming Antidepressant Therapy in Alberta

Transforming Antidepressant Therapy in Alberta

University of Calgary


Antidepressants are one of the most commonly used medications by Albertans and other Canadians. Although these drugs are generally considered to be safe and effective, many people that take these medications experience undesirable side effects that are preventable.

Pharmacogenomic testing is a special type of genetic testing that can be used to identify individuals at greatest risk for undesirable effects of these medications. In Alberta this testing is not yet offered by Alberta Health Services. However, a team of researchers and doctors from the Universities of Calgary and Alberta are currently developing a pharmacogenomic testing service that aims to improve the safety and effectiveness of antidepressant medications for Albertans.

This project is looking for input and feedback from a diverse group of individuals with lived experience of depression and antidepressant medications to inform and guide our plans for pharmacogenomic testing in Alberta.


Roles and Responsibilities

This is an opportunity to engage and contribute your essential lived experience as a patient partner on our advisory board. Patient partners would be expected to join in quarterly (4 times per year) online Zoom meeetings with the project team as well as email communication. They will be asked to share their views and insights on the current plans and contribute to the design of pharmacogenomic testing to assist doctors in prescribing antidepressant medications in Alberta.


Time Commitment

The start of this 3 year project is dependent on whether or not it is funded by Alberta Health Services (AHS). If funded, the anticipated start date will be in the Spring of 2021. Patient partners will be expected to contribute to 12 meetings over the 3 year period of the project. Some email communication between meetings will also be expected.



Compensation will be offered at approximately $900 for the full advisory panel commitment and engagement.

There are no travel costs expected.


If you would like further information, or to apply please contact:

Chad Bousman